Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Cleveland Clinic Cancer Center
mi
from
Cleveland, OH
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Cleveland Clinic Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
University of Oklahoma College of Medicine
mi
from
Oklahoma City, OK
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
University of Oklahoma College of Medicine
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center
mi
from
Tulsa, OK
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center
mi
from
Tulsa, OK
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
CCOP - Columbia River Program
mi
from
Portland, OR
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
CCOP - Columbia River Program
mi
from
Portland, OR
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Abington Memorial Hospital
mi
from
Abington, PA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Pennsylvania Hospital
mi
from
Philadelphia, PA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Pennsylvania Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
CCOP - MainLine Health
mi
from
Wynnewood, PA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
CCOP - MainLine Health
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Medical University of South Carolina
mi
from
Charleston, SC
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
CCOP - Greenville
mi
from
Greenville, SC
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
CCOP - Baptist Cancer Institute
mi
from
Memphis, TN
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
CCOP - Baptist Cancer Institute
mi
from
Memphis, TN
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Simmons Cancer Center - Dallas
mi
from
Dallas, TX
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Simmons Cancer Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
CCOP - Scott and White Hospital
mi
from
Temple, TX
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
CCOP - Scott and White Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Cancer Center, University of Virginia HSC
mi
from
Charlottesville, VA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Cancer Center, University of Virginia HSC
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
University of Washington Medical Center
mi
from
Seattle, WA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
Tacoma General Hospital
mi
from
Tacoma, WA
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
Tacoma General Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/11/2018
NCIC-Clinical Trials Group
mi
from
Kingston,
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/11/2018
NCIC-Clinical Trials Group
mi
from
Kingston,
Click here to add this to my saved trials
Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents
Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents
Status: Enrolling
Updated:  4/17/2018
Children's Hospital at Montefiore
mi
from
Bronx, NY
Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents
Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents
Status: Enrolling
Updated: 4/17/2018
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer
Strategies to Increase the Identification, Genetic Counseling Referral and Genetic Testing for Women at Risk for Hereditary Breast and/or Ovarian Cancer
Status: Enrolling
Updated:  4/18/2018
Emory University Hospital Midtown
mi
from
Atlanta, GA
Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer
Strategies to Increase the Identification, Genetic Counseling Referral and Genetic Testing for Women at Risk for Hereditary Breast and/or Ovarian Cancer
Status: Enrolling
Updated: 4/18/2018
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer
Strategies to Increase the Identification, Genetic Counseling Referral and Genetic Testing for Women at Risk for Hereditary Breast and/or Ovarian Cancer
Status: Enrolling
Updated:  4/18/2018
Winship Cancer Institute
mi
from
Atlanta, GA
Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer
Strategies to Increase the Identification, Genetic Counseling Referral and Genetic Testing for Women at Risk for Hereditary Breast and/or Ovarian Cancer
Status: Enrolling
Updated: 4/18/2018
Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Women's Activity and Lifestyle Study in Connecticut
Impact of Exercise on Ovarian Cancer Prognosis
Status: Enrolling
Updated:  4/18/2018
Yale University
mi
from
New Haven, CT
Women's Activity and Lifestyle Study in Connecticut
Impact of Exercise on Ovarian Cancer Prognosis
Status: Enrolling
Updated: 4/18/2018
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated:  4/25/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated: 4/25/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated:  4/25/2018
Memoral Sloan Kettering Basking Ridge
mi
from
Basking Ridge, NJ
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated: 4/25/2018
Memoral Sloan Kettering Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated:  4/25/2018
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated: 4/25/2018
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Click here to add this to my saved trials
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated:  4/25/2018
Memorial Sloan Kettering Commack
mi
from
Commack, NY
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated: 4/25/2018
Memorial Sloan Kettering Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated:  4/25/2018
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated: 4/25/2018
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Click here to add this to my saved trials
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated:  4/25/2018
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Status: Enrolling
Updated: 4/25/2018
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer
Status: Enrolling
Updated:  4/26/2018
City of Hope Medical Center
mi
from
Duarte, CA
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer
Status: Enrolling
Updated: 4/26/2018
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing NY-ESO-1 Protein With MIS416 Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated:  4/27/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing NY-ESO-1 Protein With MIS416 Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated: 4/27/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
Univ of Minnesota
mi
from
Minneapolis, MN
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
University Hospital of Cleveland, Case Medical Center, Seidman Cancer Center
mi
from
Cleveland, OH
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
University Hospital of Cleveland, Case Medical Center, Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated:  4/30/2018
Institut Jules Bordet
mi
from
Bruxelles,
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
Status: Enrolling
Updated: 4/30/2018
Institut Jules Bordet
mi
from
Bruxelles,
Click here to add this to my saved trials
Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer
Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer
Status: Enrolling
Updated:  5/1/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer
Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer
Status: Enrolling
Updated: 5/1/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK® Administered to Patients With Advanced Stage Ovarian Cancer
Status: Enrolling
Updated:  5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK® Administered to Patients With Advanced Stage Ovarian Cancer
Status: Enrolling
Updated: 5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors
Status: Enrolling
Updated:  5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors
Status: Enrolling
Updated: 5/1/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials